Economic evaluation is becoming increasingly important in the field of stroke as well. The results of economic evaluation can be expressed in cost per quality-adjusted life years (QALY) gained, which enables policy makers to compare the relative efficiency of different interventions regarding different diseases. Although using the concept of QALY is preferable from a theoretical point of view, in medical practice more often cost-effectiveness analysis (CEA), and not cost-utility analysis, is applied for practical reasons. One of the main limitations of CEA is that the results may be compared only with results of other CEAs, using the same effect parameter. The calculation of cost-effectiveness ratios (CERs) in many cases is misleading for resource allocation. Effects should be expressed in interval or ratio scales in order to calculate CERs, which is rarely the case. The calculation of a CER in a CEA should only be performed if, and only if, the investigator is convinced that there is a constant relation between the specific effect parameter and the ultimate gain in health.

Keywords:
Cost-effectiveness analysis, Cost-utility analysis, Decision making, Quality-adjusted life years, incremental cost, Outcome measurement, Resource allocation, Stroke
1.
Drummond MF, O’Brien B, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programs, ed 2. Oxford, Oxford University Press, 1997.
2.
Gold M, Siegel J, Russel L, Weinstein M: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996.
3.
Banta HD, Luce BR: Health Care Technology and Its Assessment: An International Perspective. Oxford, Oxford University Press, 1993.
4.
Phelps CE, Mushlin AI: On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care 1991;7:12–21.
5.
Birch S, Gafni A: Cost effectiveness/utility analyses: Do current decision rules lead us to where we want to be? J Health Econ 1992;11:279–296.
6.
Johannesson M, Weinstein M: On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459–467.
7.
Ament A, Baltussen R: The interpretation of results of economic evaluation: Explicating the value of health. Health Econ 1997;6:625–635.
8.
Torrance GW, Feeney DH: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559–579.
9.
Haddix AC, Teutsch SM, Shaffer PA, Dunet DO: Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Oxford, Oxford University Press, 1996.
10.
Spilker B: Quality of Life Assessments in Clinical Trials. New York, Raven Press, 1990.
11.
Patrick DL, Erickson P: Health Status and Health Policy: Allocating Resources to Health Care. New York, Oxford University Press, 1993.
12.
Kamlet MS: The Comparative Benefits Modelling Project: A Framework for Cost-Utility Analysis of Government Health Care Programs. Washington, US Department of Health and Human Services, 1992.
13.
Karlsson G, Johannesson M: The decision rules of cost-effectiveness analysis. Pharmaco-economics 1996;9:113–120.
14.
Froberg DG, Kane RL: Methodology for measuring health-state preferences. J Clin Epidemiol 1989;42:459–471.
15.
Lanzieri CF, Tarr RW: Cost-effectiveness of emergency intraarterial intracerebral thrombolysis: A pilot study. Am J Neuroradiol 1995;16:1987–1993.
16.
Bowling A: Measuring Disease, a Review of Disease Specific Quality of Life Measurement Scales. Buckingham, Open University Press, 1995.
17.
Britton M, Jonsson E: Diagnosing suspected stroke: A cost-effectiveness analysis. Int J Technol Assess Health Care 1985;1:147–158.
18.
Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. N Engl J Med 1995;333:1392–1400.
19.
McMahon S, Peto R, Cutler JA: Blood pressure, stroke, and coronary heart disease. I. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
20.
Weinstein MC, Fineberg HV: Clinical Decision Analysis. Philadelphia, Saunders, 1980.
21.
Torrance GW, Feeney D: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559–575.
22.
Garber AM, Phelps CE: Economic Foundations of Cost-Effectiveness Analysis. Stanford, National Bureau of Economic Research, 1993.
23.
Culyer A: The normative economics of health care finance and provision. Oxf Rev Econ Policy 1989;5:34–58.
24.
Johannesson M, Meltzer D: Some reflections on cost-effectiveness analysis. Health Econ 1998;7:1–7.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.